Sunshine Biopharma Inc. 8-K

What Happened
Sunshine Biopharma Inc. (and its wholly owned subsidiary Nora Pharma Inc.) announced on July 8, 2026 that they entered into a Release Agreement with Malek Chamoun, the former president of Nora. Under the agreement the Company agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement was disclosed in a Form 8-K filed July 10, 2026 (Item 1.01).

Key Details

• Parties: Sunshine Biopharma Inc., Nora Pharma Inc. (wholly owned subsidiary) and Malek Chamoun (former Nora president).
• Amount: CAD$1,500,000 (≈US$1,058,565) to be paid as full and final settlement.
• Date of agreement: July 8, 2026; 8-K filing date: July 10, 2026.
• Filing: Release Agreement is attached as Exhibit 10.1 to the 8-K.

Why It Matters
This is a material settlement reported under Item 1.01, meaning the company has agreed to a defined cash obligation to resolve a dispute with a former executive. For investors, the key takeaways are the payment amount and that the matter is described as a full and final settlement, which removes this specific dispute as an ongoing legal uncertainty disclosed by the company. Review the full Release Agreement (Exhibit 10.1) and recent financial filings for any disclosures on timing of payment and impact on cash or operations.